A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Exclusion Criteria

• •Subjects who participated in any other study in which receipt of an investigational study drug or device occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose.
• •Has received a prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study drug.
• •Has had prior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment.
• •Has received prior approved radiotherapy within 14 days of study therapy.
• •Has had known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry.
• •Has an active autoimmune disease that has required systemic treatment in past 2 years.
• •Has an active infection requiring systemic therapy.
• •Has known active CNS metastases and/or carcinomatous meningitis.
• •Women who are pregnant or breastfeeding.